Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Urological cancer

Abiraterone and its place in the treatment of metastatic CRPC

Nature Reviews Clinical Oncology volume 10, pages 6–8 (2013)Cite this article

Subjects

An update of the COU-AA-301 study confirms a survival advantage with abiraterone–prednisone compared to prednisone in post-docetaxel patients with metastatic castration-resistant prostate cancer. We place these data in the context of earlier disease states and other novel agents and explore practical issues concerning the future use of abiraterone.

Key Points

The most recent update of the COU-AA-301 trial dataset confirms the benefit of abiraterone in patients with metastatic castration-resistant prostate cancer who have previously received docetaxel—the challenge that lies ahead is positioning the drug appropriately in an increasingly complex treatment paradigm.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Fizazi, K. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 13, 983–992 (2012).

    Article  CAS  Google Scholar 

  2. Scher, H. I. et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26, 1148–1159 (2008).

    Article  Google Scholar 

  3. Attard, G. et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 27, 3742–3748 (2009).

    Article  CAS  Google Scholar 

  4. Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187–1197 (2012).

    Article  CAS  Google Scholar 

  5. Ryan, C. J. et al. Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) [abstract]. J. Clin. Oncol. 30 (Suppl.), LBA4518 (2012).

    Article  Google Scholar 

  6. Parker, C. et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases [abstract]. J. Clin. Oncol. 30 (Suppl. 5), a8 (2012).

    Article  Google Scholar 

  7. Pal, S. K., Lewis, B. & Sartor, O. Management of docetaxel failures in metastatic castrate-resistant prostate cancer. Urol. Clin. North Am. 39, 583–591 (2012).

    Article  Google Scholar 

  8. Mezynski, J. et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann. Oncol. 23, 2943–2947 (2012).

    Article  CAS  Google Scholar 

  9. Albiges, L. et al. Response to cabazitaxel in the post-chemotherapy setting in CRPC patients previously treated with docetaxel and abiraterone acetate [abstract]. Ann. Oncol. 23, a951 (2012).

    Article  Google Scholar 

  10. Bolla, M. et al. Duration of androgen suppression in the treatment of prostate cancer. N. Engl. J. Med. 360, 2516–2527 (2009).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medicine & Urology, Tulane Medical School, Box SL-42, 1430 Tulane Avenue, New Orleans, 70112, LA, USA

    Oliver Sartor

  2. Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, 91010, CA, USA

    Sumanta K. Pal

Authors
  1. Oliver Sartor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sumanta K. Pal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Oliver Sartor.

Ethics declarations

Competing interests

O. Sartor acts as a consultant for Algeta, Amgen, Bavarian-Nordic, Bayer, Bellicum, Bristol-Myers Squibb, Celgene, Dendreon, Exelixis, GlaxoSmithKline, Johnson & Johnson, Medivation, OncoGeneX, Pfizer, Sanofi-Aventis and Takeda. In addition, he receives research funding from Algeta, Bayer, Exelixis, Dendreon, Johnson & Johnson, Sanofi-Aventis and Takeda. S. K. Pal receives honoraria from Astellas, Novartis, Pfizer and Sanofi-Aventis. He acts as a consultant for Allos, Aveo, Genentech, Novartis and Sanofi-Aventis, and received research funding from GlaxoSmithKline.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sartor, O., Pal, S. Abiraterone and its place in the treatment of metastatic CRPC. Nat Rev Clin Oncol 10, 6–8 (2013). https://doi.org/10.1038/nrclinonc.2012.202

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2012.202

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing